广誉远(600771.SH):控股子公司拟申请授信额度1.3亿元
格隆汇3月18日丨广誉远(600771.SH)公布,公司第七届董事会第二次会议召开,经会议认真审议,通过了《公司关于为控股子公司申请银行综合授信提供担保的议案》。
为进一步拓宽融资渠道,提高资金管理水平,公司控股子公司山西广誉远国药有限公司根据其生产经营和业务发展的需要,拟分别向晋中银行股份有限公司太谷支行和中国银行股份有限公司太原漪汾支行申请总额不超过3000万元和1亿元的综合授信额度,拟申请的授信额度合计为1.3亿元。公司拟为其向上述银行申请的综合授信提供连带责任保证,并授权董事长在上述担保额度内代表公司办理相关手续,签署相关法律文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.